Kelkar SS, Prabhu VS, Corman S, Odak S, Rusibamayila N, Macahilig C, Orlowski R, Duska L. Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer who are microsatellite instability (MSI)-high or are mismatch repair deficient (dMMR) in the United States. Gynecol Oncol. 2023 Feb 1;169:154-63. doi: 10.1016/j.ygyno.2022.10.016
Haggerty A, Barrett A, Dine J, Martin L, Shah P, Buckingham T. Shared decision making in frontline maintenance therapy for ovarian cancer: a qualitative assessment. Poster presented at the 2022 Society of Gynecologic Oncology Annual Meeting; March 18, 2022. Phoenix, AZ. [abstract] Gynecol Oncol. 2022 Aug; 166(Supplement 1):S286. doi: 10.1016/S0090-8258(22)01810-8
Pajouheshnia R, van Smeden M, Peelen LM, Groenwold RHH. Variation in the measurement of predictors affects the discriminative ability and transportability of a prediction model. Presented at the Methods for Evaluation of Medical Prediction Models, Tests and Biomarkers (MEMTAB) 2018 Symposium; July 2, 2018. Utrecht, The Netherlands. [abstract] Diagn Progn Res. 2018 Jul 2; 2(Suppl 1):40. doi: 10.1186/s41512-018-0036-3
Damen JAAG, Debray TPA, Pajouheshnia R, Reitsma JB, Scholten RJPM, Moons KGM, Hooft L. Empirical evidence on the impact of study characteristics on the performance of prognostic models: a meta-epidemiological study. Presented at the Methods for Evaluation of Medical Prediction Models, Tests and Biomarkers (MEMTAB) 2018 Symposium; July 2, 2018. Utrecht, The Netherlands. [abstract] Diagn Progn Res. 2018 Jul 2; 2(Suppl 1):29-30. doi: 10.1186/s41512-018-0036-3
Pajouheshnia R, Schuster NA, Moons KGM, Rutten FH, Groenwold RHH, Peelen LM. Accounting for time-varying treatments when developing a prognostic model: a case study in patients treated with betablockers. Poster presented at the Methods for Evaluation of Medical Prediction Models, Tests and Biomarkers (MEMTAB) 2018 Symposium; July 2018. Utrecht, Netherlands. [abstract] Diagn Progn Res. 2018 Jul; 2(Supp1):28-9. doi: 10.1186/s41512-018-0036-3
Pajouheshnia R, Damen JAAG, Groenwold RHH, Moons KGM, Peelen LM. Treatment use in prognostic model research: a systematic review of cardiovascular prognostic studies. Diagn Progn Res. 2017 Sep 26;1:15. doi: 10.1186/s41512-017-0015-0
Heus P, Damen JAAG, Pajhouheshnia R, Scholten RJPM, Reitsma JM, Collins GS, Altman DG, Moons KGM, Hooft L. More than half of the TRIPOD items are inadequately reported in prediction modelling studies. Poster presented at the Methods for Evaluating Medical Tests and Biomarkers 2016 Symposium; July 19, 2016. Birmingham, UK. [abstract] Diagn Progn Res. 2017 Feb 16; 1(Suppl 1):27. doi: 10.1186/s41512-016-0001-y
Pajouheshnia R, Groenwold R, Moons K, Reitsma J, Peelen L. The effects of treatment use when externally validating a prediction model that did not include treatment as predictor. Presented at the Methods for Evaluating Medical Tests and Biomarkers 2016 Symposium; February 2016. Birmingham, United Kingdom. [abstract] Diagn Progn Res. 2017 Feb 16; 1(Suppl 1):12. doi: 10.1186/s41512-016-0001-y
Pajouheshnia R, Damen J, Groenwold R, Moons K, Peelen L. How treatment use is addressed in prognostic research: a systematic review. Poster presented at the Methods for Evaluating Medical Tests and Biomarkers 2016 Symposium; July 19, 2016. Birmingham, UK. [abstract] Diagn Progn Res. 2017 Feb 16; 1(Suppl 1):19. doi: 10.1186/s41512-016-0001-y
Damen JAAG, Debray TPA, Heus P, Hooft L, Moons KGM, Pajouheshnia R, Reitsma JB, Scholten RJPM. Design characteristics of external validation studies influencing the performance of risk prediction models. Poster presented at the Methods for Evaluating Medical Tests and Biomarkers 2016 Symposium; July 2016. Birmingham, UK. [abstract] Diagn Progn Res. 2017 Feb 16; 1(Suppl 1):21. doi: 10.1186/s41512-016-0001-y
Damen JAAG, Debray TPA, Heus P, Hooft L, Moons KGM, Pajouheshnia R, Reitsma JB, Scholten RJPM. Performance of the Framingham risk models and pooled cohort equations for the prediction of cardiovascular disease in the general population: a meta-analysis. Poster presented at the Methods for Evaluating Medical Tests and Biomarkers 2016 Symposium; July 19, 2016. Birmington, UK. [abstract] Diagn Progn Res. 2017 Feb 16; 1(Suppl 1):20-1. doi: 10.1186/s41512-016-0001-y
Colosia AD, Palencia R, Khan S. Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review. Diabetes Metab Syndr Obes. 2013 Sep 17;6:327-38.
Dizon D, Meyers J. The economic burden of ovarian cancer in a US managed care database. Poster presented at the 41st Annual Meeting of the Society of Gynecologic Oncologists; March 2010. [abstract] Gynecol Oncol. 2010 Mar; 116((3) Suppl 1):S121.
Foster T, Brown TM, Chang J, Menssen HD, Blieden MB, Herzog TJ. A review of the current evidence for maintenance therapy in ovarian cancer. Gynecol Oncol. 2009 Nov 1;115:290-301.
Neubauer NL, Havrilesky LJ, Calingaert B, Bulusu A, Bernardini MQ, Fleming ND, Bland AE, Secord AA. The role of lymphadenectomy in the management of preoperative grade 1 endometrial carcinoma. Gynecol Oncol. 2009 Mar;112(3):511-6.
Bland AE, Calingaert B, Secord AA, Lee PS, Valea FA, Berchuck A, Soper JT, Havrilesky L. Relationship between tamoxifen use and high risk endometrial cancer histologic types. Gynecol Oncol. 2009 Jan 1;112(1):150-4.
Curtis B, Hayes RP, Fehnel S, Zografos L. Assessing the effect of weight and weight loss in obese persons with type 2 diabetes. Diabetes Metab Syndr Obes. 2008 Oct 1;1:13-23.
Secord AA, Havrilesky LJ, Bae-Jump V, Chin J, Calingaert B, Bland A, Rutledge TL, Berchuck A, Clarke-Pearson DL, Gehrig PA. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer. Gynecol Oncol. 2007 Nov 1;107(2):285-91.
Havrilesky LJ, Secord AA, Bae-Jump V, Ayeni T, Calingaert B, Clarke-Pearson DL, Berchuck A, Gehrig PA. Outcomes in surgical stage I uterine papillary serous carcinoma. Gynecol Oncol. 2007 Jun 1;105(3):677-82.
Havrilesky LJ, Cragun JM, Calingaert B, Secord AA, Valea FA, Clarke-Pearson DL, Berchuck A, Soper JT. The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer. Gynecol Oncol. 2007 Feb 1;104(2):401-5.
Maxwell GL, Schildkraut JM, Calingaert B, Risinger JI, Dainty L, Marchbanks PA, Berchuck A, Barrett JC, Rodriguez GC. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk. Gynecol Oncol. 2006 Nov 1;103(2):535-40.
Lutman CV, Havrilesky LJ, Cragun JM, Secord AA, Calingaert B, Berchuck A, Clarke-Pearson DL, Soper JT. Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology. Gynecol Oncol. 2006 Jul 1;102(1):92-7.
Havrilesky LJ, Cragun JM, Calingaert B, Synan I, Secord AA, Soper JT, Clarke-Pearson DL, Berchuck A. Resection of lymph node metastases influences survival in stage IIIC endometrial cancer. Gynecol Oncol. 2005 Dec 1;99(3):689-95.
Spillman MA, Schildkraut JM, Halabi S, Moorman P, Calingaert B, Bentley RC, Marks JR, Murphy S, Berchuck A. Transforming growth factorbeta receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk. Gynecol Oncol. 2005 May 1;97(2):543-9.
Havrilesky LJ, Leath CA, Huh W, Calingaert B, Bentley RC, Soper JT, Secord AA. Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer. Gynecol Oncol. 2004 May 1;93(2):429-34.
Vine MF, Calingaert B, Berchuck A, Schildkraut JM. Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls. Gynecol Oncol. 2003 Jul 1;90(1):75-82.
Vine MF, Ness RB, Calingaert B, Schildkraut JM, Berchuck A. Types and duration of symptoms prior to diagnosis of invasive or borderline ovarian tumor. Gynecol Oncol. 2001 Dec;83(3):466-71.